Akero Therapeutics

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKRO and other ETFs, options, and stocks.

About AKRO

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. 

CEO
Andrew Cheng
CEOAndrew Cheng
Employees
33
Employees33
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2017
Founded2017
Employees
33
Employees33

AKRO Key Statistics

Market cap
1.97B
Market cap1.97B
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
606.94K
Average volume606.94K
High today
$42.77
High today$42.77
Low today
$40.34
Low today$40.34
Open price
$41.29
Open price$41.29
Volume
466.11K
Volume466.11K
52 Week high
$48.24
52 Week high$48.24
52 Week low
$7.52
52 Week low$7.52

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

AKRO Earnings

-$0.93
-$0.62
-$0.31
-$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Feb 24, After Hours
ActualExpected Feb 24, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.